Skip to Content
MilliporeSigma
All Photos(2)

Documents

SML0245

Sigma-Aldrich

Candesartan cilexetil

≥98% (HPLC)

Synonym(s):

2-ethoxy-1-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-1H-Benzimidazole-7-carboxylic acid 1-[[(cyclohexyloxy)carbonyl]oxy]ethyl ester, TCV 116, TCY 116

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C33H34N6O6
CAS Number:
Molecular Weight:
610.66
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77

Quality Level

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: ≥15 mg/mL

originator

Takeda

storage temp.

2-8°C

SMILES string

CCOc1nc2cccc(C(=O)OC(C)OC(=O)OC3CCCCC3)c2n1Cc4ccc(cc4)-c5ccccc5-c6nnn[nH]6

InChI

1S/C33H34N6O6/c1-3-42-32-34-28-15-9-14-27(31(40)43-21(2)44-33(41)45-24-10-5-4-6-11-24)29(28)39(32)20-22-16-18-23(19-17-22)25-12-7-8-13-26(25)30-35-37-38-36-30/h7-9,12-19,21,24H,3-6,10-11,20H2,1-2H3,(H,35,36,37,38)

InChI key

GHOSNRCGJFBJIB-UHFFFAOYSA-N

Gene Information

human ... AGTR1(185)

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Candesartan cilexetil is the prodrug form of the potent angiotensin II receptor antagonist, candesartan. The prodrug is cleaved by esterases within the intestine to liberate the active molecule.

Features and Benefits

This compound is featured on the Angiotensin Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Takeda. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

Health hazardEnvironment

signalword

Warning

Hazard Classifications

Aquatic Acute 1 - Repr. 2

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 9

1 of 9

Candesartan cilexetil British Pharmacopoeia (BP) Reference Standard

BP1248

Candesartan cilexetil

Olmesartan ≥98% (HPLC)

Sigma-Aldrich

SML1394

Olmesartan

Azilsartan ≥98% (HPLC)

Sigma-Aldrich

SML0432

Azilsartan

Olmesartan medoxomil ≥98% (HPLC)

Sigma-Aldrich

SML1391

Olmesartan medoxomil

Telmisartan ≥98% (HPLC), solid

Sigma-Aldrich

T8949

Telmisartan

Geranylgeranylacetone

Sigma-Aldrich

G5048

Geranylgeranylacetone

Ji-Young Jeon et al.
Drug development and industrial pharmacy, 39(9), 1296-1299 (2012-10-04)
Candesartan is a long-acting and selective nonpeptide AT1 subtype angiotensin II receptor antagonist. The aim of this study was to compare the pharmacokinetics and to evaluate the bioequivalence of two candesartan cilexetil 16 mg formulations. Forty healthy volunteers were randomly assigned
Po-Yin Chu et al.
PloS one, 10(7), e0133616-e0133616 (2015-07-28)
Heart failure (HF) is an increasingly recognized complication of diabetes. Cardiac fibrosis is an important causative mechanism of HF associated with diabetes. Recent data indicate that inflammation may be particularly important in the pathogenesis of cardiovascular fibrosis. We sought to
Greg L Plosker et al.
PharmacoEconomics, 24(12), 1249-1272 (2006-11-30)
The addition of candesartan cilexetil (Atacand, Amias, Blopress, Kenzen, Ratacand) to standard therapy for chronic heart failure (CHF) provided important clinical benefits at little or no additional cost in France, Germany and the UK, according to a detailed economic analysis
Gerd Bönner et al.
Current medical research and opinion, 21(6), 935-940 (2005-06-23)
Candesartan cilexetil is a highly potent and long-acting angiotensin II type I (AT1) receptor antagonist. This short review summarises results of clinical studies focusing on the duration of action of candesartan cilexetil. Results of previous clinical studies indicate that candesartan
G Mancia et al.
Journal of human hypertension, 14 Suppl 2, S3-10 (2000-11-22)
The prevention and treatment of hypertension both from the viewpoint of individual patient care and in terms of population health presents a considerable challenge to the medical profession. To assist in meeting this challenge, various bodies have produced guidelines for

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service